HUMMINGBIRD BIOSCIENCES LIMITED

Hummingbird Biosciences Limited is at the forefront of precision medicine, engineering next‑generation biotherapeutics that aim to reshape the treatment landscape for patients who do not respond to existing options. Drawing on deep expertise in biologics discovery and development, the company leverages its proprietary linker‑payload technologies to create highly differentiated antibody‑based therapies, including antibody‑drug conjugates (ADCs), that target cancer and autoimmune diseases with strong biological rationale and clinical validation.

The firm’s core services span the full drug‑development continuum: from target identification and precision‑therapy design, through to the execution of global clinical trials that maximise the probability of success and accelerate patient access. Hummingbird’s pipeline features a suite of novel antibody therapeutics, with imminent proof‑of‑concept read‑outs, and recent milestones such as the first patient dosed in a Phase I trial of HMBD‑501 for HER3‑expressing solid tumours and the licensing of the Phase II‑ready candidate HMBD‑002.

By combining cutting‑edge engineering with a patient‑centred focus, Hummingbird Biosciences delivers hope to those in need of more effective, durable treatments, positioning itself as a leading innovator in the precision‑medicine arena.